Interview: Aurélien Chaufour – Managing Director, Anjac, France
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
Created in 2008, Anjac Health and Beauty consists of four experts and complementary companies in the areas of health, hygiene, beauty. Anjac is much more than a manufacturer who formulates, manufactures and packages products for companies in the areas of health, beauty and hygiene. Their added value is an ability to imagine and develop innovative customized solutions that make a difference to clients.
Today Anjac has four companies that are expert in the fields of health, hygiene and beauty. First, Shadeline, dynamic company specializing in dermatology and cosmetics. Second, Euro Wipes, a major player in the wipes market, offering a full range of wipes and impregnated cotton pads. Third, Sicaf, a well-established partner of luxury cosmetic brands, known for its expertise in formulation, manufacturing and custom packaging. And lastly, Chemineau, a European specialist in contract development and manufacturing of pharmaceutical products, cosmetics and medical devices. In total they have five manufacturing and R&D facilities. Each year more than a thousand formulations and five thousand products are conceived, manufactured and packaged in their five sites.
Contact
15, rue de la Banque,
75002, PARIS
T : +33 1 53 45 94 49
F : +33 1 53 45 94 59
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
The latest news from French pharma, including why President Emmanuel Macron’s initiative to bring medical production back to Europe has hit a wall, Sanofi’s slow progress towards finally bringing its…
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for their work on COVID-19 vaccines, smaller and lesser-known companies are also playing…
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19 vaccine as it faces delays with its in-house product and the…
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales growth in 2020 despite the pandemic, diagnostics…
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s new Chinese acquisition catapults it into the world’s top 5 CDMOs, Ipsen’s resilient…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic…
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679 million in vaccine manufacturing operations in the next two…
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed CEO of fellow French firm Ipsen on the 28th May 2020, effective 1st July. Loew,…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He…
See our Cookie Privacy Policy Here
